549 related articles for article (PubMed ID: 17483326)
1. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
Knowles HJ; Athanasou NA
J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
Hiraga T; Myoui A; Choi ME; Yoshikawa H; Yoneda T
Cancer Res; 2006 Feb; 66(4):2067-73. PubMed ID: 16489006
[TBL] [Abstract][Full Text] [Related]
4. Significance of HIF-1-active cells in angiogenesis and radioresistance.
Harada H; Kizaka-Kondoh S; Li G; Itasaka S; Shibuya K; Inoue M; Hiraoka M
Oncogene; 2007 Nov; 26(54):7508-16. PubMed ID: 17563752
[TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
[TBL] [Abstract][Full Text] [Related]
6. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
7. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer.
Kizaka-Kondoh S; Itasaka S; Zeng L; Tanaka S; Zhao T; Takahashi Y; Shibuya K; Hirota K; Semenza GL; Hiraoka M
Clin Cancer Res; 2009 May; 15(10):3433-41. PubMed ID: 19417024
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.
Harada H; Hiraoka M; Kizaka-Kondoh S
Cancer Res; 2002 Apr; 62(7):2013-8. PubMed ID: 11929818
[TBL] [Abstract][Full Text] [Related]
10. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
11. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha.
Fox SB; Bragança J; Turley H; Campo L; Han C; Gatter KC; Bhattacharya S; Harris AL
Cancer Res; 2004 Sep; 64(17):6075-81. PubMed ID: 15342390
[TBL] [Abstract][Full Text] [Related]
12. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
Yoneda T; Williams PJ; Hiraga T; Niewolna M; Nishimura R
J Bone Miner Res; 2001 Aug; 16(8):1486-95. PubMed ID: 11499871
[TBL] [Abstract][Full Text] [Related]
13. Insulin-dependent leptin expression in breast cancer cells.
Bartella V; Cascio S; Fiorio E; Auriemma A; Russo A; Surmacz E
Cancer Res; 2008 Jun; 68(12):4919-27. PubMed ID: 18559540
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.
Gordon AH; O'Keefe RJ; Schwarz EM; Rosier RN; Puzas JE
Cancer Res; 2005 Apr; 65(8):3209-17. PubMed ID: 15833852
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration.
Postovit LM; Abbott DE; Payne SL; Wheaton WW; Margaryan NV; Sullivan R; Jansen MK; Csiszar K; Hendrix MJ; Kirschmann DA
J Cell Biochem; 2008 Apr; 103(5):1369-78. PubMed ID: 17685448
[TBL] [Abstract][Full Text] [Related]
16. Nuclear co-localization and functional interaction of COX-2 and HIF-1α characterize bone metastasis of human breast carcinoma.
Maroni P; Matteucci E; Luzzati A; Perrucchini G; Bendinelli P; Desiderio MA
Breast Cancer Res Treat; 2011 Sep; 129(2):433-50. PubMed ID: 21069452
[TBL] [Abstract][Full Text] [Related]
17. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.
Zhao Y; Bachelier R; Treilleux I; Pujuguet P; Peyruchaud O; Baron R; Clément-Lacroix P; Clézardin P
Cancer Res; 2007 Jun; 67(12):5821-30. PubMed ID: 17575150
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
Rucci N; Millimaggi D; Mari M; Del Fattore A; Bologna M; Teti A; Angelucci A; Dolo V
Cancer Res; 2010 Aug; 70(15):6150-60. PubMed ID: 20631064
[TBL] [Abstract][Full Text] [Related]
19. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
Baker AF; Koh MY; Williams RR; James B; Wang H; Tate WR; Gallegos A; Von Hoff DD; Han H; Powis G
Pancreas; 2008 Mar; 36(2):178-86. PubMed ID: 18376310
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-1 in human breast and prostate cancer.
Kimbro KS; Simons JW
Endocr Relat Cancer; 2006 Sep; 13(3):739-49. PubMed ID: 16954428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
